At a Glance
Therapeutic Area:
Acute Myeloid Leukemia (AML)
Approved Applications:
Applications In Development:
Vosaroxin is a first-in-class anticancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin exerts potent anticancer activity through a mechanism that involves intercalation into DNA and an inhibition of topoisomerase II activity that results in replication-dependent, site-selective double-strand breaks in DNA.
In clinical trials conducted to date, vosaroxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.
Acquisition Date:
March 2012
Royalty Seller:

"It is our goal to see vosaroxin, an unpartnered asset and one of the most advanced and promising therapies in development for AML today, change the global standard of care in this disease. With continued support and enthusiasm from our investigators and stakeholders, as well as a strong balance sheet, we remain well positioned to achieve this goal."
Daniel Swisher, CEO of Sunesis
© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.